Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
about
JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatinRegulation of chromatin by histone modificationsPersonalized medicine in gastric cancer: Where are we and where are we going?Targeting the tumor microenvironment: JAK-STAT3 signalingGenomic profiling of B-progenitor acute lymphoblastic leukemiaJanus kinase inhibitors in autoimmune diseasesJAK2 activation by growth hormone and other cytokinesSelf-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansionAZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell linesEpstein-Barr virus-positive gastric cancer: a distinct molecular subtype of the disease?CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patientsRandom mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitorNovel multiplexed assay for identifying SH2 domain antagonists of STAT family proteinsTyrosine kinase inhibitors for the treatment of rheumatoid arthritisMouse models of myeloproliferative neoplasms: JAK of all gradesETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cellsDetection of mutations in myeloid malignancies through paired-sample analysis of microdroplet-PCR deep sequencing data.Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase.Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities.Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.Comparative analysis of the JAK/STAT signaling through erythropoietin receptor and thrombopoietin receptor using a systems approach.Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice.A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosisDC - SIGNR by influencing the lncRNA HNRNPKP2 upregulates the expression of CXCR4 in gastric cancer liver metastasis.Defining the blueprint of the cancer genome.ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.Endogenous retrovirus induces leukemia in a xenograft mouse model for primary myelofibrosis.Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosisDetection of exon 12 Mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing.Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosisCo-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasmsCombination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.c-Abl activates janus kinase 2 in normal hematopoietic cells.DNA damage stress and inhibition of Jak2-V617F cause its degradation and synergistically induce apoptosis through activation of GSK3βMiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2.Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformationClinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humansModulation of innate and adaptive immune responses by tofacitinib (CP-690,550).
P2860
Q24318979-7A22AB1B-17C4-4EF0-BBB2-3AFB8C9E1CB2Q24635070-AA96E2CC-A9EE-4B65-8285-AF194917404AQ26774521-33EB1EDA-C807-435F-99F7-166D692BF896Q26825658-2F90F191-C786-4FAF-89AD-2DDBB5FDECBEQ26829976-45918BB7-D79D-4256-8FD0-5AE97B33C759Q26865446-45828571-8E25-4568-9B39-93C86643F25FQ27003058-680EF2B5-C320-4EE0-98B2-52090FEC57A1Q27317353-24B4BF0F-0240-42E8-9B29-D87A2A5FB29CQ27851932-1D13176C-A02D-4350-BE9A-251F30FA7456Q28075698-8E2B6B21-505D-4526-95EE-25CD2835EED1Q28238474-E991885F-A05A-4F2A-90A6-272F9D92691CQ28482297-508515D7-0E0E-4A99-90AA-F7DEBD3D92F5Q28535402-FFC25206-5144-438C-9C84-572804090851Q28674280-6B1E187A-A15C-45A3-8A67-AF73BC009E39Q28744478-3403E511-FC5E-49E1-B1C7-E2FD1AD7150EQ28754852-AA672683-4C1C-47D8-817A-78509B2E6023Q30836256-73A69E4B-3D69-401E-AEC0-D5B51FFECE79Q33390032-CEA1E0B7-2084-4F15-A8AF-E86C2F0E7688Q33396730-B6BEADE0-BBBF-47CA-B789-FABDE13BFD97Q33398180-2971B09B-5A38-4C7E-81C6-6BC32A12D370Q33407887-D36D519C-480F-4AC5-ABB6-016C4D1C3EFDQ33419130-41903978-F2B5-4EA0-94CB-1523DF6DFE11Q33434284-9480F800-267C-4897-AF6E-BB189D9601D5Q33560349-2EACD4F8-02D8-4A27-8872-E1D3296595EBQ33671802-E30A1807-1F2E-4CB8-A0F3-D751E2049E8EQ33687080-564EDCDE-EB5E-4114-BFEE-F3B6C9C36E85Q33767496-B0F3CC44-2348-4B46-8499-894F946271D1Q33771667-DF192E98-8189-43DB-BA98-8F1BA2C6AFB9Q33788714-69CCE48D-1C11-4F89-93B7-99D8DA3E1A67Q33813824-6808E7FB-0A83-4843-AEEA-DEA91EA0A783Q33886243-A2A8EC40-0E02-4E58-B8AD-3650458F6661Q33982315-DD704C3B-59F8-4ED8-9593-048443D32C22Q33982322-F884B853-8536-46DD-B4E7-1C6AB45217D1Q33985308-31F04658-7769-47A1-9BFD-6076CA5D0464Q34075662-270F2CF3-AFB4-4E19-8905-EDEBE0BDF2ACQ34120830-95824693-D2C2-44FD-91A5-24B8B568B49CQ34124973-913904BD-2911-422C-9A86-9BB6C8493EB5Q34147910-9DE01A00-75C1-48E1-8841-168E16E52C0FQ34162151-267182EB-9237-475E-93F1-CC7A99EFC6FDQ34169114-105BE282-7D6B-4864-A7D3-B19FEDBC7C37
P2860
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
@en
type
label
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
@en
prefLabel
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
@en
P2093
P356
P1476
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
@en
P2093
Animesh Pardanani
D Gary Gilliland
Ross L Levine
P2888
P304
P356
10.1038/NRC2210
P407
P577
2007-09-01T00:00:00Z
P6179
1031385333